Patent application number | Description | Published |
20090004117 | Self-Illiminating Dot Systems and Methods of Use Thereof - Generally, aspects of the present disclosure are directed to conjugate systems, self-illuminating quantum dot conjugates, methods of detecting a target in a host, methods of treating a disease in a host, and the like. | 01-01-2009 |
20090044286 | Estrogen receptor intramolecular folding systems, estrogen receptor intramolecular folding sensors, methods of use thereof, methods of detecting ER ligands, and methods of detecting ER agonists and antagonists - Briefly described, embodiments of this disclosure include estrogen receptor (ER) intramolecular folding systems, methods of detecting ER ligands and distinguishing between ER agonists and antagonists, cells including ER intramolecular folding systems, transgenic animals including ER intramolecular folding systems, fusion proteins, and the like. | 02-12-2009 |
20090075309 | Bisdeoxycoelenterazine derivatives, methods of use, and BRET2 systems - Embodiments of the present disclosure provide for: compositions, BRET systems, kits, and the like. | 03-19-2009 |
20090169474 | METHOD FOR NONINVASNELY AND QUANTITATIVELY MONITORING THERAPEUTIC AND DIAGNOSTIC TRANSGENE EXPRESSION INDUCED BY EX VNO AND IN VNO GENE TARGETING IN ORGANS, TISSUES AND CELLS - An composition in a method for noninvasively monitoring the expression of therapeutic transgene delivered ex vivo and in vivo for the treatment of diseases includes the step of quantitatively imaging a reporter gene expression which is coupled to a therapeutic gene on a plasmid vector to infer levels, location, or duration of the therapeutic gene expression in the targeted tissues or organs. The reporter gene is imaged using a radiopharmaceutical for scintigraphic imaging of the gene expression interactions with the reporter gene, namely positron emission tomography, gamma camera or single-photon emission computed tomography. The genes are delivered with a liposome encapsulated reporter-therapeutic linked transgene vector with balanced reporter/therapeutic transgene expression. A transgene composition includes the reporter gene linked to the therapeutic gene or genes incorporated in and delivered by a liposome encapsulated reporter-therapeutic linked transgene vector. | 07-02-2009 |
20090257952 | Engineered Integrin Binding Peptides - Engineered peptides that bind with high affinity (low equilibrium dissociation constant (Kd)) to the cell surface receptors of fibronectin (α | 10-15-2009 |
20100032575 | METHODS AND SYSTEMS FOR PET/CT SCANNING FOR EVALUATION OF MALIGNANCY - Embodiments of the methods of the present disclosure allow interpretation of the | 02-11-2010 |
20100047813 | BIOLUMINESCENCE RESONANCE ENERGY TRANSFER (BRET) SYSTEMS AND METHODS OF USE THEREOF - Briefly described, embodiments of this disclosure include bioluminescence resonance energy transfer (BRET) systems, methods of detecting a protein-protein interaction, noninvasive methods for detecting the interaction of a first protein with a second protein within a living animal, methods to determine the efficacy of a test compound administered to modulate the interaction of a first protein with a second protein in a living animal, BRET vectors, kits relating to each of the above, transgenic cell or progeny thereof and/or animals relating to each of the above, and the like. | 02-25-2010 |
20100074845 | ENHANCED SENSITIVITY CARBON NANOTUBES AS TARGETED PHOTOACOUSTIC MOLECULAR IMAGING AGENTS - The present disclosure provides contrast photoacoustic probes, and compositions comprising such probes, designed to non-invasively detect and monitor various disease states, or targets within a subject human or animal. The probes are designed to be optically excited in tissue, ultimately generating thermal energy, which is transformed into acoustic energy by the response of the aqueous environment in the subject to the thermal emissions. The acoustic energy (sound) can then be detected by suitably applied transducers and digitally transformed into images indicating the location of the probe in the subject. One aspect of the disclosure encompasses photoacoustic probes that comprise: a carbon nanotube and a plurality of dye molecules bound to the carbon nanotube. The probes may further comprise a targeting moiety for localizing the probe at the site of a specific target. Another aspect of the present disclosure encompasses methods of detecting a target in animal or human subject, comprising: delivering a photoacoustic probe to a subject, allowing the photoacoustic probe to selectively bind to a target of the subject; and illuminating the system with an optical energy absorbable by the photoacoustic probe to generate an acoustic signal; and detecting the acoustic signal, thereby detecting the target in the subject. | 03-25-2010 |
20100111871 | PHOTOACOUSTIC PROBES AND METHODS OF IMAGING - Embodiments of the present disclosure provide for photoacoustic probes, methods of determining the presence and location of a specific target, methods of determining the presence and location of an enzyme, methods of determining the presence and location of a specific target and an enzyme, and the like. | 05-06-2010 |
20100135912 | MAGNETOTACTIC BACTERIA MRI POSITIVE CONTRAST ENHANCEMENT AGENT AND METHODS OF USE - Magnetic resonance imaging (MRI) is enhanced by contrast agents such as superparamagnetic iron-oxide (SPIO) particles that resemble magnetite particles produced by magnetotactic bacteria. | 06-03-2010 |
20100169993 | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists - Briefly described, embodiments of this disclosure include ligand-regulable transactivation systems, methods of producing ligand-regulable transactivation systems, methods of using ligand-regulable transactivation systems, reporter polynucleotides, method of producing reporter polynucleotides, activator fusion proteins, methods of producing activator fusion proteins, methods of regulating gene expression in vitro and in vivo for gene therapy, methods of screening estrogen receptor modulators with therapeutic treatments (e.g., anticancer, antiosteoporosis, and hormone replacement treatments), method of screening compounds (e.g., drugs and environmental pollutants) for the estrogenic effect, methods of evaluating the estrogen receptor pathway under different pathological conditions are provided, and the like. | 07-01-2010 |
20100322861 | ENGINEERED CELLS, IMAGING REPORT GENE/PROBE SYSTEMS, AND METHODS OF IMAGING - Embodiments of the present disclosure provide: methods of imaging the location and survival of an engineered cell in a host (e.g., human) with an imaging reporter probe, methods of imaging the location and survival of an engineered cell in a host, and, kits, engineered cells, and methods of making the engineered cells, and the like. | 12-23-2010 |
20120179029 | PROBES, METHODS OF MAKING PROBES, AND METHODS OF USE - Embodiments of the present disclosure provide for probes, methods of using the probe, methods of making the probe, method of imaging a condition (e.g., pre-cancerous tissue, cancer, or a tumor), methods of planning resection of a brain tumor, methods of imaging a brain tumor, and the like. | 07-12-2012 |
20120220870 | OPTICAL IMAGING PROBES, OPTICAL IMAGING SYSTEMS, METHODS OF OPTICAL IMAGING, AND METHODS OF USING OPTICAL IMAGING PROBES - Embodiments of the present disclosure provide for radionuclide probes, methods of using the radionuclide probes, methods of detecting an optical signal from radionuclides, methods of detecting an optical signal from a quantum dot(s) that receives optical energy from a radionuclide(s), system for analyzing optical energy emitted by a radionuclide(s), system for imaging a target within a living subject or a sample, methods of imaging a disease or condition, and the like. | 08-30-2012 |
20120269734 | Self-Illuminating Dot Systems and Methods of Use Thereof - Generally, aspects of the present disclosure are directed to conjugate systems, self-illuminating quantum dot conjugates, methods of detecting a target in a host, methods of treating a disease in a host, and the like. | 10-25-2012 |
20120270914 | SPLIT-LUCIFERASE C-MYC SENSOR AND USES THEREOF - A split luciferase-based sensor system was developed to noninvasively monitor and image phosphorylation-mediated c-Myc activation, in which the complementation of the split FL is induced by phosphorylation-mediated interaction between GSK3β and c-Myc. The complemented luciferase activity resulting from this interaction is specific to c-Myc phosphorylation and correlated with the steady-state and temporal regulation of c-Myc phosphorylation in cell culture. The sensor system also allows monitoring of c-Myc—targeted drug efficacy in intact cells and living animals. This new imaging sensor can provide insight into the role of functional c-Myc in cancer biology and is useful for the discovery and development of specific anti-c-Myc drugs. | 10-25-2012 |
20120323112 | NANOPARTICLES FOR ACCOUSTIC IMAGING, METHODS OF MAKING, AND METHODS OF ACCOUSTIC IMAGING - Embodiments of the present disclosure provide for nanoparticles for acoustic imaging, methods of using the nanoparticles, methods of imaging a condition, and the like. Embodiments of the present disclosure include nanoparticles (e.g., silica nanoparticles) that can be used to image, detect, study, monitor, evaluate, and/or screen a sample or subject (e.g., whole-body or a portion thereof). | 12-20-2012 |
20130224122 | MAGNETOTATIC BACTERIA MRI POSITIVE CONTRACT ENHANCEMENT AGENT AND METHODS OF USE - Magnetic resonance imaging (MRI) is enhanced by contrast agents such as superparamagnetic iron-oxide (SPIO) particles that resemble magnetite particles produced by magnetotactic bacteria. | 08-29-2013 |
20130310347 | MULTI-MODALITY MOLECULAR IMAGING HIGH-THROUGHPUT ASSAY FOR IDENTIFYING HEAT SHOCK PROTEIN 90 (HSP90) INHIBITORS - High throughput methods for identifying novel inhibitors of Hsp90 chaperone protein folding are disclosed. The inhibitors so identified disrupt the binding of p23 to either Hsp90α or Hsp90β and have selective activity against the proliferation of cancer cells. In particular are provided embodiments of therapeutic compositions that comprise at least one inhibitor of an Hsp90 chaperone activity, the inhibitor being any of the compounds designated as CP1-CP19 as shown in FIGS. | 11-21-2013 |
20140255305 | IMMUNO IMAGING AGENT FOR USE WITH ANTIBODY-DRUG CONJUGATE THERAPY - The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6. | 09-11-2014 |
20140271467 | PROBES AND METHODS OF IMAGING NON-HODGKINS LYMPHOMA - Embodiments of the present disclosure provide for labeled probes such as a | 09-18-2014 |
20140271475 | CELLULOSE NANOPARTICLE BIODEGRADABLE PHOTOACOUSTIC CONTRAST AGENTS - Biodegradable cellulose photoacoustic probes are provided that are able to detect biological targets and generate a detectable photoacoustic signal. The cellulose nanoparticles are biodegradable by cellulases. Clearance of the nanoparticles from a subject is enhanced and results in improved contrast of a photoacoustic-generated image. Methods to generate images by administering a cellulose nanoparticle probes to a subject and irradiating with light of a wavelength to emit photoacoustic energy detectable by sensors external to the subject are also provided. The detectable signal is convertible to a visual image of the nanoparticle probes in the subject. The methods may include allowing a cellulase to degrade nanoparticles so that undesirable background signals emitted are substantially reduced to increase the contrast and quality of the generated image. In the absence of an endogenous source of an enzyme for degrading the cellulose nanoparticles, a composition comprising a heterologous cellulase may be administered along with the nanoparticles. | 09-18-2014 |
20140275073 | METHODS OF TREATING CANCER SENSITIVE TO ANTI-EGFR THERAPY AND MODIFYING TREATMENT USING BLOOD BIOMARKERS - The present disclosure provides methods of treating cancer and modifying a cancer treatment for a cancer with an anti-EGFR drug by creating PRDX6 expression profiles and using the profiles to evaluate and optionally modify treatment. The present disclosure also provides assays and systems for assessing sensitivity of a cancer to an anti-EGFR therapy. | 09-18-2014 |
20140314671 | PROBES AND METHODS OF IMAGING A BACTERIAL INFECTION - Embodiments of the present disclosure provide for labeled probes such as labeled maltose probes and labeled acarbose probes, methods of making labeled probes, pharmaceutical compositions including labeled probes, methods of using labeled probes, methods of diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, kits for diagnosing, localizing, monitoring, and/or assessing bacterial infections, using labeled probes, and the like. | 10-23-2014 |
20150071859 | TUMOR-SPECIFIC MINICIRCLES FOR CANCER SCREENING - The present disclosure encompasses embodiments of nucleic acid minicircle vectors most advantageous for the detection of tumor cells. In particular, the minicircles of the disclosure incorporate a tumor-specific promoter operably linked to a nucleotide sequence desired to be selectively expressed in a tumor cell or a tissue comprising a population of tumor cells. In embodiments of the disclosure, the minicircle vectors comprise a tumor-specific promoter operably linked to a nucleotide sequence encoding a polypeptide useful as a reporter. Accordingly, when expressed by a recipient tumor cell, the reporter may be detectable, thereby providing information such as a visual image of the tumor cell and/or its location in a tissue of the subject human or non-human animal. Tumor-specific minicircle vectors driving the expression of either secreted embryonic alkaline phosphatase or firefly luciferase and their utility validated for detecting tumors after systemic administration using blood- and/or imaging-based assays are disclosed. | 03-12-2015 |